Key result
Insulin glargine and omega-3 fail to reduce PAD incidence or progression in dysglycemia.
Why the study?
The impact of insulin or omega-3 supplements on the incidence and progression of peripheral artery disease in patients with dysglycaemia had not been well studied.
Does insulin glargine or omega-3 prevent the incidence or progression of peripheral artery disease in patients with dysglycaemia and cardiovascular risk factors?
RCT (n=12,090)
Does insulin glargine or omega-3 prevent the incidence or progression of peripheral artery disease in patients with dysglycaemia and cardiovascular risk factors?
Answers are grounded in this paper and cite their sources.
Neither insulin glargine nor omega-3 supplementation reduces the incidence or progression of peripheral artery disease in patients with dysglycaemia and cardiovascular risk factors.
The impact of insulin or omega-3 supplements on the incidence and progression of peripheral artery disease (PAD) in patients with dysglycaemia has not been well studied. The Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial randomized participants with dysglycaemia and cardiovascular risk factors to titrated insulin glargine vs standard care, and to either 1 g of omega-3 per day or placebo. We assessed incident PAD, defined as the composite of either asymptomatic or symptomatic PAD according to the randomized interventions in the 11 119 ORIGIN participants whose baseline ankle-brachial index (ABI) was >0.9 (no PAD), and PAD progression in the 971 ORIGIN participants whose baseline ABI was ≤0.9. Hazard ratios (HR) were adjusted for confounders. During a 6.2-year follow-up period, allocation to insulin glargine vs standard care had a neutral effect on the composite of PAD incidence (HR, 0.99; 95% CI, 0.86-1.15) and progression (HR, 0.88; 95% CI, 0.63-1.22). Similar findings were noted for allocation to omega-3 vs placebo for PAD incidence (HR, 1.02; 95% CI, 0.89-1.18) and progression (HR, 0.93; 95% CI, 0.67-1.28). In this large study, neither insulin glargine nor omega-3 affected the incidence or progression of PAD.
No takes yet. Share an insight, caveat, or question.
Dagenais et al. (2019) conducted an RCT in Dysglycaemia and cardiovascular risk factors (n=12,090). Insulin glargine and omega-3 vs. Standard care and placebo was evaluated on Incident peripheral artery disease (composite of asymptomatic or symptomatic PAD) (HR 0.99, 95% CI 0.86-1.15). In patients with dysglycaemia, neither insulin glargine nor omega-3 affected the incidence or progression of peripheral artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: